465 assets in Obesity Disorder

Therapeutic assets addressing Obesity Disorder, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]- Obesity Disorder	Hospital General Tlahuac	P4	CCC (54)
Saroglitazar Obesity Disorder	Zydus Lifesciences Limited	P4	CCC (54)
Symtuza Obesity Disorder	East Carolina University	P4	CCC (54)
Tradipitant Obesity Disorder	Vanda Pharmaceuticals	P3	CCC (54)
4H-1-BENZOPYRAN-4-ONE, 8-.BETA.-D-GLUCOPYRANOSYL-7-HYDROXY-3-(4-HYDROXYPHENYL)- Obesity Disorder	Ruijin Hospital	P2	CCC (53)
Aphd-002 Obesity Disorder	Aphaia Pharma US LLC	P2	CCC (53)
Aphp-002 Obesity Disorder	Aphaia Pharma US LLC	P2	CCC (53)
Aphp-012 Obesity Disorder	Aphaia Pharma US LLC	P2	CCC (53)
bio101 Obesity Disorder	Biophytis	P2	CCC (53)
ck-0045 Obesity Disorder	Cytoki Pharma	P2	CCC (53)
Doxycycline Obesity Disorder	Mayo Clinic	P4	CCC (53)
ecc4703 Obesity Disorder	Eccogene	P2	CCC (53)
emp16-120/40 Obesity Disorder	Empros Pharma AB	P2	CCC (53)
emp16-60/20 Obesity Disorder	Empros Pharma AB	P2	CCC (53)
hsg4112 Obesity Disorder	Glaceum	P2	CCC (53)
k-757 Obesity Disorder	Kallyope Inc.	P2	CCC (53)
K-833 Obesity Disorder	Kallyope Inc.	P2	CCC (53)
L-Prolinamide, N-(19-Carboxy-1-Oxononadecyl)-L-?-Glutamyl-L-Arginyl-L-?-Aspartylglycyl-L-Threonyl-L-Alanyl-L-Threonyl-L-Lysyl-L-Alanyl-L-Threonyl-L-?-Glutamyl-L-Arginyl-L-Leucyl-L-Alanyl-5-Carboxy-L-Norvalyl-L-Phenylalanyl-L-Leucyl-L-Glutaminyl-L-Arginyl-L-Seryl-L-Seryl-L-Phenylalanyl-N-Methylglycyl-L-Alanyl-N-Methyl-L-Isoleucyl-L-Leucyl-L-Seryl-L-Seryl-L-Threonyl-L-?-Glutamyl-L-Valylglycyl-L-Seryl-L-Asparaginyl-L-Threonyl-4-Hydroxy-, (3?8)-Lactam, (4R)- Obesity Disorder	Hoffmann-La Roche	P2	CCC (53)
ly3549492 Obesity Disorder	Eli Lilly and Company	P2	CCC (53)
Mitochondria-Derived Peptide Mots-C Obesity Disorder	Hudson Biotech	P2	CCC (53)
na-931 Obesity Disorder	Biomed Industries, Inc.	P2	CCC (53)
nnc0174-0833 Obesity Disorder	Novo Nordisk A/S	P2	CCC (53)
nnc0519-0130 Obesity Disorder	Novo Nordisk A/S	P2	CCC (53)
Olatorepatide Obesity Disorder	Regeneron Pharmaceuticals	P2	CCC (53)
Pregabalin Obesity Disorder	Medical University of Warsaw	P4	CCC (53)
s-309309 Obesity Disorder	Shionogi	P2	CCC (53)
Tcr .Alpha..Beta. (Receptor), Anti-(Human P53 (Protein)) (Synthetic Human Single-Chain Precursor) Fusion Protein With Interleukin 2 (Human) Obesity Disorder	Altimmune, Inc.	P2	CCC (53)
Vancomycin Obesity Disorder	Assaf Harofeh MC	P2	CCC (53)
asc47 Obesity Disorder	Ascletis Pharma (China) Co., Limited	P1	CCC (52)
Duratocin Obesity Disorder	Cairo University	P1/2	CCC (52)
Dynamos Obesity Disorder	Beijing QL Biopharmaceutical Co.,Ltd	P1	CCC (52)
rgt001-075 Obesity Disorder	Regor Pharmaceuticals Inc.	P2	CCC (52)
Triticum Aestivum Obesity Disorder	Coordinación de Investigación en Salud, Mexico	P3	CCC (52)
Diethylpropion Obesity Disorder	Louisiana State University Health Sciences Center in New Orleans	P4	CCC (51)
Eplerenone Obesity Disorder	Hippocration General Hospital	P4	CCC (51)
Lomaira Obesity Disorder	Loma Linda University	P4	CCC (51)
Rosuvastatin Obesity Disorder	Beijing QL Biopharmaceutical Co.,Ltd	P1	CCC (51)
Azithromycin Obesity Disorder	University of Oklahoma	P2	CCC (50)
Bictegravir Obesity Disorder	José Antonio Mata Marín	P3	CCC (50)
Carboplatin Obesity Disorder	Hacettepe University	P3	CCC (50)
Cilastatin Obesity Disorder	University of Illinois at Chicago	P4	CCC (50)
Clonidine Obesity Disorder	University of Kansas Medical Center	P2	CCC (50)
Dapiglutide Obesity Disorder	Zealand Pharma	P2	CCC (50)
erx1000 Obesity Disorder	ERX Pharmaceuticals	P2	CCC (50)
(±)-Ftc Obesity Disorder	José Antonio Mata Marín	P3	CCC (50)
Garetosmab Obesity Disorder	Regeneron Pharmaceuticals	P2	CCC (50)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Mstn (Myostatin, Growth Differentiation Factor 8, Gdf8, Gdf-8) Latent Myostatin Complex], Humanized Monoclonal Antibody; Obesity Disorder	Hoffmann-La Roche	P2	CCC (50)
Kai-7535 Obesity Disorder	Kailera	P2	CCC (50)
Kai-9531 Obesity Disorder	Kailera	P3	CCC (50)
Macupatide Obesity Disorder	Eli Lilly and Company	P2	CCC (50)

Showing 151 to 200 of 465 assets

PreviousPage 4 of 10Next